Want to see GB:IMM full AI Analyst Report?
IMM Stock Chart & Stats
3.50 p
-0.48 p(-10.67%)
At close: 4:00 PM EDT
3.50 p
-0.48 p(-10.67%)
Day’s Range― - ―
52-Week Range3.02 p - 14.00 p
Previous CloseN/A
Volume1.18M
Average Volume (3M)2.33M
Market Cap
£25.58M
Enterprise Value20.22M
Total Cash (Recent Filing)£695.84K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield17.86%
Share Statistics
EPS (TTM)-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume3,616,301
30 Day Avg. Volume2,333,072
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageDebt at or near zero reduces default and refinancing pressure, preserving financial flexibility while ImmuPharma advances its development portfolio. A lightly leveraged balance sheet also avoids adding substantial interest costs to a business that is not yet generating meaningful operating revenue.
Improved Capital PositionThe move to positive equity and higher total assets provides a stronger capital base than in 2024. Although profitability remains absent, this improvement can support continued research activity and gives the company more balance-sheet capacity than its earlier negative-equity position.
Partnership-Based Monetisation ModelA partnering-led model allows ImmuPharma to pursue value from proprietary drug candidates without building a large integrated sales and marketing organization. If development progresses, licensing, milestones, royalties, and collaboration income provide several potential monetisation routes.
Bears Say
Minimal Revenue BaseThe absence of a meaningful revenue base leaves ImmuPharma dependent on future clinical progress, partnerships, or financing rather than recurring operating income. This limits internal funding capacity and makes the business economically sensitive to the timing and success of asset development.
Widening Net LossesThe sharp increase in net losses indicates that current research and overhead spending is not yet being supported by revenue or commercial returns. Continued deterioration in earnings can erode the capital base and increase the amount of external funding needed to sustain development.
Persistent Cash BurnSustained negative operating and free cash flow means the company is not currently self-funding its activities. Ongoing cash burn raises reliance on external financing and can constrain the pace of research, particularly if development costs continue before partnership or product income emerges.
ImmuPharma News
IMM FAQ
What was ImmuPharma PLC’s price range in the past 12 months?
ImmuPharma PLC lowest share price was 3.02 p and its highest was 14.00 p in the past 12 months.
What is ImmuPharma PLC’s market cap?
ImmuPharma PLC’s market cap is £25.58M.
When is ImmuPharma PLC’s upcoming earnings report date?
ImmuPharma PLC’s upcoming earnings report date is May 25, 2027 which is in 214 days.
How were ImmuPharma PLC’s earnings last quarter?
ImmuPharma PLC released its earnings results on Sep 15, 2026. The company reported -0.008 p earnings per share for the quarter.
Is ImmuPharma PLC overvalued?
According to Wall Street analysts ImmuPharma PLC’s price is currently Overvalued.
Does ImmuPharma PLC pay dividends?
ImmuPharma PLC pays a Notavailable dividend of 1 p which represents an annual dividend yield of 17.86%. See more information on ImmuPharma PLC dividends here
What is ImmuPharma PLC’s EPS estimate?
ImmuPharma PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuPharma PLC have?
ImmuPharma PLC has 623,911,400 shares outstanding.
What happened to ImmuPharma PLC’s price movement after its last earnings report?
ImmuPharma PLC reported an EPS of -0.008 p in its last earnings report. Following the earnings report the stock price went down -8.429%.
Which hedge fund is a major shareholder of ImmuPharma PLC?
Currently, no hedge funds are holding shares in GB:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Technical Analysis
Sareum Holdings
―
Scancell Holdings
―
HemoGenyx Pharmaceuticals Plc
―
SkinBioTherapeutics
―
Poolbeg Pharma Ltd.
―